Structure-activity study of pentamidine analogues as antiprotozoal agents

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 2016-2035

  Bakunova, Svetlana M ^a,b,c,d   Bakunov, Stanislav A ^a,b,c,d   Patrick, Donald A ^a,b,c,d   Kumar, E V K Suresh ^a,b,c,d   Ohemeng, Kwasi A ^a,b,c,d   Bridges, Arlene S ^a,b,c,d   Wenzler, Tanja ^a,b,c   Barszcz, Todd ^a,b,c   Jones, Susan Kilgore ^a,b,c,d   Werbovetz, Karl A ^a,b,c   Brun, Reto ^a,b,c   Tidwell, Richard R ^a,b,c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMIDINOPHENOXY) 3 (4 CARBOXYPHENOXY)PROPANE; 1 (4 AMIDINOPHENOXY) 3 [(2 IMIDAZOLINYL)BENZEN 4 OXY]PROPANE; 1 (4 AMIDINOPHENOXY) 5 (4 AMINOPHENOXY)PENTANE; 1,3 BIS(3 CHLOROBENZAMIDIN 4 OXY)PROPANE; 1,3 BIS(BENZAMIDIN 3 OXY)PROPANE; 1,3 BIS[(2 IMIDAZOLINYL) 3 OXY]PROPANE; 1,3BIS[(N ISOPROPYL)BENZAMIDIN 4 OXY]PROPANE; 1,4 BIS(BENZAMIDIN 3 OXY)BUTANE; 1,5 BIS [3 METHOXY (2 IMIDAZOLINYL)BENZEN 4 OXY]PENTANE; 1,5 BIS(2 FLUOROBENZAMIDIN 4 OXY)PENTANE; 1,5 BIS(3 METHOXYBENZAMIDIN 4 OXY)PENTANE; 1,5 BIS(4 AMIDINO 2 AMINOCARBONYLPHENOXY)PENTANE; 1,5 BIS(BENZAMIDIN 3 OXY)PENTANE; 1,5 BIS(BENZAMIDIN 4 AMINO)PENTANE; 1,5 BIS(BENZAMIDRAZON 4 OXY)PENTANE; 1,5 BIS[(1H TETRAZOLYL 5)BENZEN 4 OXY]PENTANE; 1,5 BIS[(N ISOPROPYL)BENZAMIDIN 4 AMINO]PENTANE; 1,5 BIS[(N ISOPROPYL)BENZAMIDIN 4 OXY]PENTANE; 1,5 BIS[(N METHYL)BENZAMIDIN 4 OXY]PENTANE; 1,5 BIS[3 ETHOXYCARBONYL(N ISOPROPYL)BENZAMIDIN 4 OXY]PENTANE; 1,5 BIS[4 (2 IMIDAZOLINYL)BENZEN 1 AMINO]PENTANE; 1,5 BIS[4 (ACETIMIDOYLAMINO)BENZEN 1 OXY]PENTANE; 1,5 BIS[4 (BENZIMIDOYLAMINO) BENZEN 1 OXY]PENTANE; 1,5 BIS[4 (BENZIMIDOYLAMINO)BENZEN 1 OXY]PENTANE; 1,6 BIS(BENZAMIDIN 3 OXY)HEXANE; ANTIPROTOZOAL AGENT; MELARSOPROL; PENTAMIDINE; PENTAMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; RAT; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; TRYPANOSOMA RHODESIENSE; TRYPANOSOMIASIS;

ANIMALS; ANTIMALARIALS; CADAVERINE; DRUG RESISTANCE; FEMALE; IMIDAZOLES; LEISHMANIA DONOVANI; MICE; MYOBLASTS; PARASITIC SENSITIVITY TESTS; PENTAMIDINE; PLASMODIUM FALCIPARUM; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS;

EID: 64549091432     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801547t     Document Type: Article

References (134)

1. Greenwood, B.; Mutabingwa, T. Malaria in 2002. Nature 2002, 415, 670-672.
2. Guerin, P. J.; Olliaro, P.; Nosten, F.; Druilhe, P.; Laxminarayan, R.; Binka, F.; Kilama, W. L.; Ford, N.; White, N. J. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect. Dis.2002, 2, 564-573.
3. Biagini, G. A.; O'Neill, P. M.; Bray, P. G.; Ward, S. A. Current drug development portfolio for antimalarial therapies. Curr. Opin. Pharmacol. 2005, 5, 473-478.
4. Tripathi, R. P.; Mishra, R. C.; Dwivedi, N.; Tewari, N.; Verma, S. S. Current status of malaria control. Curr. Med. Chem. 2005, 12, 2643-2659.
5. Linares, G. E.; Rodriguez, J. B. Current status and progresses made in malaria chemotherapy. Curr. Med. Chem. 2007, 14, 289-314.
6. Miller, L. H.; Baruch, D. I.; Marsh, K.; Doumbo, O. K. The pathogenic basis of malaria. Nature 2002, 415, 673-679.
7. Apted, F. I. Present status of chemotherapy and chemopropylaxis of human trypanosomiasis in the Eastern Hemisphere. Pharmacol. Ther. 1980, 11, 391-413.
8. Burri, C.; Brun, R. Human African Trypanosomiasis. In Manson's Tropical Diseases; Cook, G. C., Zumla, A., Eds.;W. B. Saunders: London, 2008; pp 1307-1325.
9. Maudlin, I. African trypanosomiasis. Ann. Trop. Med. Parasitol. 2006, 100, 679-701.
10. Simarro, P. P.; Jannin, J.; Cattand, P. Eliminating human African trypanosomiasis: Where do we stand and what comes next? PLoS Med. 2008, 5, 174-180.
11. Barrett, M. P.; Boykin, D. W.; Brun, R.; Tidwell, R. R. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. Pharmacol. 2007, 152, 1155-1171.
12. Herwaldt, B. L. Leishmaniasis. Lancet 1999, 354, 1191-1199.
13. Guerin, P. J.; Olliaro, P.; Sundar, S.; Boelaert, M.; Croft, S. L.; Desjeux, P.; Wasunna, M. K.; Bryceson, A. D. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2002, 2, 494-501.
14. Croft, S. L.; Yardley, V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 2002, 8, 319-342.
15. Singh, S.; Sivakumar, R. Challenges and new discoveries in the treatment of leishmaniasis. J. Infect. Chemother. 2004, 10, 307-315.
16. Mishra, J.; Saxena, A.; Singh, S. Chemotherapy of leishmaniasis: past, present and future. Curr. Med. Chem. 2007, 14, 1153-1169.
17. Weina, P. J.; Neafie, R. C.; Wortmann, G.; Polhemus, M.; Aronson, N. E. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin. Infect. Dis. 2004, 39, 1674-1680.
18. Peters, B. S.; Fish, D.; Golden, R.; Evans, D. A.; Bryceson, A. D.; Pinching, A. J. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q. J. Med. 1990, 77, 1101-1111.
19. Cruz, I.; Nieto, J.; Moreno, J.; Canavate, C.; Desjeux, P.; Alvar, J. Leishmania/HIV co-infections in the second decade. Indian J. Med. Res. 2006, 123, 357-388.
20. Walker, M.; Kublin, J. G.; Zunt, J. R. Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis. Clin. Infect. Dis. 2006, 42, 115-125.
21. Karp, C. L.; Auwaerter, P. G. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin. Infect. Dis. 2007, 45, 1208-1213.
22. Lloyd-Smith, J. O.; Poss, M.; Grenfell, B. T. HIV-1/parasite co-infection and the emergence of new parasite strains. Parasitology 2008, 135, 795-806.
23. Pintado, V.; Martin-Rabadan, P.; Rivera, M. L.; Moreno, S.; Bouza, E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001, 80, 54-73.
24. Wolday, D.; Berhe, N.; Akuffo, H.; Desjeux, P.; Britton, S. Emerging Leishmania/HIV co-infection in Africa. Med. Microbiol. Immunol. 2001, 190, 65-67.
25. Desjeux, P.; Alvar, J. Leishmania/HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol. 2003, 97 (Suppl 1), 3-15.
26. Rabello, A.; Orsini, M.; Disch, J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann. Trop. Med. Parasitol. 2003, 97 (Suppl 1), 17-28.
27. Bronzan, R. N.; Taylor, T. E.; Mwenechanya, J.; Tembo, M.; Kayira, K.; Bwanaisa, L.; Njobvu, A.; Kondowe, W.; Chalira, C.; Walsh, A. L.; Phiri, A.; Wilson, L. K.; Molyneux, M. E.; Graham, S. M. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J. Infect. Dis. 2007, 195, 895-904.
28. Sartori, A. M.; Ibrahim, K. Y.; Nunes Westphalen, E. V.; Braz, L. M.; Oliveira, O. C., Jr.; Gakiya, E.; Lopes, M. H.; Shikanai-Yasuda, M. A. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann. Trop. Med. Parasitol. 2007, 101, 31-50.
29. Wongsrichanalai, C.; Pickard, A. L.; Wernsdorfer, W. H.; Meshnick, S. R. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2002, 2, 209-218.
30. Le Bras, J.; Durand, R. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam. Clin. Pharmacol. 2003, 17, 147-153.
31. Arav-Boger, R.; Shapiro, T. A. Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge. Annu. ReV. Pharmacol. Toxicol. 2005, 45, 565-585.
32. Hyde, J. E. Drug-resistant malaria. Trends Parasitol. 2005, 21, 494-498.
33. Platteeuw, J. J. Resistance to sulphadrug-based antifolate therapy in malaria: are we looking in the right place? Trop. Med. Int. Health 2006, 11, 804-808.
34. Woodrow, C. J.; Krishna, S. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cell Mol. Life. Sci. 2006, 63, 1586-1596.
35. Brun, R.; Schumacher, R.; Schmid, C.; Kunz, C.; Burri, C. The phenomenon of treatment failures in human African trypanosomiasis. Trop. Med. Int. Health 2001, 6, 906-914.
36. Fairlamb, A. H. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 2003, 19, 488-494.
37. Sundar, S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2001, 6, 849-854.
38. Sundar, S.; Chatterjee, M. Visceral leishmaniasisscurrent therapeutic modalities. Indian J. Med. Res. 2006, 123, 345-352.
39. Jha, T. K. Drug unresponsiveness and combination therapy for kalaazar. Indian J. Med. Res. 2006, 123, 389-398.
40. Barrett, M. P.; Gilbert, I. H. Perspectives for new drugs against trypanosomiasis and leishmaniasis. Curr. Top. Med. Chem. 2002, 2, 471-482.
41. Loiseau, P. M.; Bories, C. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators. Curr. Top. Med. Chem. 2006, 6, 539-550.
42. Murray, H. W.; Berman, J. D.; Davies, C. R.; Saravia, N. G. Advances in leishmaniasis. Lancet 2005, 366, 1561-1577.
43. Sundar, S.; Jha, T. K.; Thakur, C. P.; Sinha, P. K.; Bhattacharya, S. K. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 2007, 356, 2571-2581.
44. Ashley, J. N.; Barber, H. J.; Ewins, A. J.; Newbery, G.; Self, A. D. H. Chemotherapeutic comparison of the trypanocidal action of some aromatic diamidines. J. Chem. Soc. 1942, 103-116.
45. Bouteille, B.; Oukem, O.; Bisser, S.; Dumas, M. Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol. 2003, 17, 171-181.
46. Pearson, R. D.; Hewlett, E. L. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases. Ann. Intern. Med. 1985, 103, 782-786.
47. Goa, K. L.; Campoli-Richards, D. M. Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 1987, 33, 242-258.
48. Monk, J. P.; Benfield, P. Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia. Drugs 1990, 39, 741-756.
49. Bray, P. G.; Barrett, M. P.; Ward, S. A.; de Koning, H. P. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 2003, 19, 232-239.
50. Bell, C. A.; Hall, J. E.; Kyle, D. E.; Grogl, M.; Ohemeng, K. A.; Allen, M. A.; Tidwell, R. R. Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob. Agents Chemother. 1990, 34, 1381-1386.
51. Stead, A. M.; Bray, P. G.; Edwards, I. G.; DeKoning, H. P.; Elford, B. C.; Stocks, P. A.; Ward, S. A. Diamidine compounds: selective uptake and targeting in Plasmodium falciparum. Mol. Pharmacol. 2001, 59, 1298-1306.
52. Docampo, R.; Moreno, S. N. Current chemotherapy of human African trypanosomiasis. Parasitol. Res. 2003, 90 (Supp 1), S10-13.
53. Burchmore, R. J.; Ogbunude, P. O.; Enanga, B.; Barrett, M. P. Chemotherapy of human African trypanosomiasis. Curr. Pharm. Des. 2002, 8, 256-267.
54. Legros, D.; Ollivier, G.; Gastellu-Etchegorry, M.; Paquet, C.; Burri, C.;Jannin,J.;Buscher,P.TreatmentofhumanAfricantrypanosomiasisspresent situation and needs for research and development. Lancet Infect. Dis. 2002, 2, 437-440.
55. Das, B. P.; Boykin, D. W. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J. Med. Chem. 1977, 20, 531-536.
56. Steck, E. A.; Kinnamon, K. E.; Davidson, D. E., Jr.; Duxbury, R. E.; Johnson, A. J.; Masters, R. E. Trypanosoma rhodesiense: evaluation of the antitrypanosomal action of 2,5-bis(4-guanylphenyl)furan dihydrochloride. Exp. Parasitol. 1982, 53, 133-144.
57. Ulrich, P.; Cerami, A. Trypanocidal 1,3-arylene diketone bis(guanylhydrazone) s. Structure-activity relationships among substituted and heterocyclic analogues. J. Med. Chem. 1984, 27, 35-40.
58. Bell, C. A.; Cory, M.; Fairley, T. A.; Hall, J. E.; Tidwell, R. R. Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNAbinding affinity. Antimicrob. Agents Chemother. 1991, 35, 1099-1107.
59. Blagburn, B. L.; Sundermann, C. A.; Lindsay, D. S.; Hall, J. E.; Tidwell, R. R. Inhibition of Cryptosporidium parVum in neonatal Hsd:(ICR)BR Swiss miceby polyether ionophores and aromatic amidines. Antimicrob. Agents Chemother. 1991, 35, 1520-1523.
60. Lindsay, D. S.; Blagburn, B. L.; Hall, J. E.; Tidwell, R. R. Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures. Antimicrob. Agents Chemother. 1991, 35, 1914-1916.
61. Boykin, D. W. Antimicrobalactivity of the DNA minor groove binders furamidine and analogs. J. Braz. Chem. Soc. 2002, 13, 763-771.
62. Brendle, J. J.; Outlaw, A.; Kumar, A.; Boykin, D. W.; Patrick, D. A.; Tidwell, R. R.; Werbovetz, K. A. Antileishmanial activities of several classes of aromatic dications. Antimicrob. Agents Chemother. 2002, 46, 797-807.
63. Soeiro, M. N.; De Souza, E. M.; Stephens, C. E.; Boykin, D. W. Aromatic diamidines as antiparasitic agents. Expert Opin. InVestig. Drugs 2005, 14, 957-972.
64. Werbovetz, K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr. Opin. InVestig. Drugs 2006, 7, 147-157.
65. Walzer, P. D.; Kim, C. K.; Foy, J.; Linke, M. J.; Cushion, M. T. Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 1988, 32, 896-905.
66. Tidwell, R. R.; Jones, S. K.; Geratz, J. D.; Ohemeng, K. A.; Cory, M.; Hall, J. E. Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. J. Med. Chem. 1990, 33, 1252-1257.
67. Jones, S. K.; Hall, J. E.; Allen, M. A.; Morrison, S. D.; Ohemeng, K. A.; Reddy, V. V.; Geratz, J. D.; Tidwell, R. R. Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 1990, 34, 1026-1030.
68. Donkor, I. O.; Jones, S. K.; Tidwell, R. R. Pentamidine congeners 1: Synthesis of cis- and trans-Butamidine analogues as anti-Pneumocystis carinii pneumonia agents. Bioorg. Med. Chem. Lett. 1993, 3, 1137-1140.
69. Donkor, I. O.; Tidwell, R. R.; Jones, S. K. Pentamidine congeners. 2. 2-Butene-bridged aromatic diamidines and diimidazolines as potential anti-Pneumocystis carinii pneumonia agents. J. Med. Chem. 1994, 37, 4554-4557.
70. Boykin, D. W.; Kumar, A.; Spychala, J.; Zhou, M.; Lombardy, R. J.; Wilson, W. D.; Dykstra, C. C.; Jones, S. K.; Hall, J. E.; Tidwell, R. R.; Laughton, C.; Nunn, C. M.; Neidle, S. Dicationic diarylfurans as anti-Pneumocystis carinii agents. J. Med. Chem. 1995, 38, 912-916.
71. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Anti-pneumocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg. Med. Chem. Lett. 1996, 6, 3017-3020.
72. Huang, T. L.; Zhang, Q.; White, A. T.; Queener, S. F.; Bartlett, M. S.; Smith, J. W.; Donkor, I. O. Synthesis and anti-Pneumocystis carinii activity of piperidine-linked aromatic diimidazolines. Bioorg. Med. Chem. Lett. 1996, 6, 2087-2090.
73. Delia, T. J.; Nagarajan, A.; Queener, S. F.; Bartlett, M. S. Ringbased analogs of pentamidine versus P. carinii pneumonia in culture. Bioorg. Med. Chem. Lett. 1996, 6, 2367-2370.
74. Boykin, D.; Kumar, A.; Xiao, G.; D., W.; Bender, B.; McCurdy, D.; Hall, J.; Tidwell, R. 2,5-Bis[4-(N-alkylamidino)phenyl]furans as anti-Pneumocystis carinii agents. J. Med. Chem. 1998, 41, 124-129.
75. Rahmathullah, S. M.; Hall, J. E.; Bender, B. C.; McCurdy, D. R.; Tidwell, R. R.; Boykin, D. W. Prodrugs for amidines: synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl) furan. J. Med. Chem. 1999, 42, 3994-4000.
76. Tao, B.; Huang, T. L.; Zhang, Q.; Jackson, L.; Queener, S. F.; Donkor, I. O. Synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogues of pentamidine. Eur. J. Med. Chem. 1999, 34, 531-538.
77. Vanden Eynde, J. J.; Mayence, A.; Huang, T. L.; Collins, M. S.; Rebholz, S.; Walzer, P. D.; Cushion, M. T. Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia. Bioorg. Med. Chem. Lett. 2004, 14, 4545-4548.
78. Anne, J.; De Clercq, E.; Eyssen, H.; Dann, O. Antifungal and antibacterial activities of diarylamidine derivatives. Antimicrob. Agents Chemother. 1980, 18, 231-239.
79. Del Poeta, M.; Schell, W. A.; Dykstra, C. C.; Jones, S.; Tidwell, R. R.; Czarny, A.; Bajic, M.; Kumar, A.; Boykin, D.; Perfect, J. R. Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. Antimicrob. Agents Chemother. 1998, 42, 2495-2502.
80. Geratz, J. D.; Whitmore, A. C. Diamidino-R,?-diphenoxyalkanes. Structure-activity relationships for the inhibition of thrombin, pancreatic kallikrein, and trypsin. J. Med. Chem. 1973, 16, 970-975.
81. Geratz, J. D.; Cheng, M. C.; Tidwell, R. R. New aromatic diamidines with central R-oxyalkane or R,?-dioxyalkane chains. Structureactivity relationships for the inhibition of trypsin, pancreatic kallikrein, and thrombin and for the inhibition of the overall coagulation process. J. Med. Chem. 1975, 18, 477-481.
82. Geratz, J. D.; Cheng, M. C.; Tidwell, R. R. Novel bis(benzamidino) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement. J. Med. Chem. 1976, 19, 634-639.
83. Parrish, R. F.; Straus, J. W.; Paulson, J. D.; Polakoski, K. L.; Tidwell, R. R.; Geratz, J. D.; Stevens, F. M. Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives. J. Med. Chem. 1978, 21, 1132-1136.
84. Tidwell, R. R.; Geratz, J. D.; Dann, O.; Volz, G.; Zeh, D.; Loewe, H. Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of argininespecific esteroproteases. J. Med. Chem. 1978, 21, 613-623.
85. Clercq, E. D.; Dann, O. Diaryl amidine derivatives as oncornaviral DNA polymerase inhibitors. J. Med. Chem. 1980, 23, 787-795.
86. Lansiaux, A.; Dassonneville, L.; Facompre, M.; Kumar, A.; Stephens, C. E.; Bajic, M.; Tanious, F.; Wilson, W. D.; Boykin, D. W.; Bailly, C. Distribution of furamidine analogues in tumor cells: influence of the number of positive charges. J. Med. Chem. 2002, 45, 1994-2002.
87. Lansiaux, A.; Tanious, F.; Mishal, Z.; Dassonneville, L.; Kumar, A.; Stephens, C. E.; Hu, Q.; Wilson, W. D.; Boykin, D. W.; Bailly, C. Distribution of furamidine analogues in tumor cells: targeting of the nucleus or mitochondria depending on the amidine substitution. Cancer Res. 2002, 62, 7219-7229.
88. Pathak, M. K.; Dhawan, D.; Lindner, D. J.; Borden, E. C.; Farver, C.; Yi, T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol. Cancer Ther. 2002, 1, 1255-1264.
89. Baraldi, P. G.; Bovero, A.; Fruttarolo, F.; Preti, D.; Tabrizi, M. A.; Pavani, M. G.; Romagnoli, R. DNA minor groove binders as potential antitumor and antimicrobial agents. Med. Res. Rev. 2004, 24, 475-528.
90. Maciejewska, D.; Kazmierczak, P.; Zabinski, J.; Wolska, I.; Popis, S. Pentamidine analogs: syntheses, structures in solid state by 13C CP/MAS NMR spectroscopy, and X-ray crystallography and their preliminary biological screening against human cancer. Monatsh. Chem. 2006, 137, 1225-1240.
91. Steck, E. A.; Kinnamon, K. E.; Rane, D. S.; Hanson, W. L. Leishmania donoVani, Plasmodium berghei, Trypanosoma rhodesiense: antiprotozoal effects of some amidine types. Exp. Parasitol. 1981, 52, 404-413.
92. Clement, B.; Raether, W. Amidoximes of pentamidine: synthesis, trypanocidal and leishmanicidal activity. Arzneim. Forsch. 1985, 35, 1009-1014.
93. Berger, B. J.; Lombardy, R. J.; Marbury, G. D.; Bell, C. A.; Dykstra, C. C.; Hall, J. E.; Tidwell, R. R. Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob. Agents Chemother. 1990, 34, 1678-1684.
94. Kratzl, K.; Meisert, E. Chemistry of vanillin and its derivatives. X. Amidines, imidazolines, and tetrahydropyrimidinediones with guaiacol substituents. Monatsh. Chem. 1957, 88, 1056-1063.
95. Dox, A.W.; Whitmore, F. C. Acetamidine Hydrochloride. In Organic Synthesis, 2nd ed.; Blatt, A. H., Ed.; John Wiley & Sons: New York, 1941; Vol. 1, pp 5-7.
96. Berg, S. S.; Newbery, G. The Search for Chemotherapeutic Amidines Part X. Substituted 4,4'-Diamidino-R,?-diphenoxyalkanes and -diphenyl ethers. J. Chem. Soc. 1949, 642-648.
97. Willson, M.; Perie, J. J.; Malecaze, F.; Opperdoes, F.; Callens, M. Biological properties of amidinium sulfinic and sulfonic acid derivatives: inhibition of glycolytic enzymes of Trypanosoma brucei and protective effect on cell growth. Eur. J. Med. Chem. 1992, 27, 799-808.
98. Stephens, C. E.; Tanious, F.; Kim, S.; Wilson, W. D.; Schell, W. A.; Perfect, J. R.; Franzblau, S. G.; Boykin, D. W. Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents. J. Med. Chem. 2001, 44, 1741-1748.
99. Shearer, B. G.; Oplinger, J. A.; Lee, S. S-2-Naphthylmethyl thioacetimidate hydrobromide: a new odorless reagent for the mild synthesis of substituted acetamidines. Tetrahedron Lett. 1997, 38, 179-182.
100. Spychala, J. 4-(Cyclic-amidino)phenols. Preparation and use in a diamidine synthesis. Synth. Commun. 2000, 30, 1083-1094.
101. Kubota, H.; Kakefuda, A.; Watanabe, T.; Ishii, N.; Wada, K.; Masuda, N.; Sakamoto, S.; Tsukamoto, S. Synthesis and pharmacological evaluation of 1-oxo-2-(3-Piperidyl)-1,2,3,4- tetrahydroisoquinolines and related analogues as a new class of specific bradycardic agents possessing If channel inhibitory activity. J. Med. Chem. 2003, 46, 4728-4740.
102. Mackman, R. L.; Katz, B. A.; Breitenbucher, J. G.; Hui, H. C.; Verner, E.; Luong, C.; Liu, L.; Sprengeler, P. A. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator. J. Med. Chem. 2001, 44, 3856-3871.
103. Peters, W.; Davies, E. E.; Robinson, B. L. Chemotherapy of rodent malaria. XXIII. Causal prophylaxis. II. Practical experience with Plasmodium yoelii nigeriensis in drug screening. Ann. Trop. Med. Parasitol 1975, 69, 311-328.
104. Krishnamurthy, S.; Aimino, D. Rapid and selective reduction of functionalized aromatic disulfides with lithium tri-tert-butoxyaluminohydride. A remarkable steric and electronic control. Comparison of various hydride reagents. J. Org. Chem. 1989, 54, 4458-4462.
105. Liang, X.; Jie, C.; Trudell, M. L. Chromium(VI) oxide catalyzed oxidation of sulfides to sulfones with periodic acid. J. Org. Chem. 2003, 68, 5388-5391.
106. Bacchi, C. J.; Brun, R.; Croft, S. L.; Alicea, K.; Buhler, Y. In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob. Agents Chemother. 1996, 40, 1448-1453.
107. Donkor, I. O.; Assefa, H.; Rattendi, D.; Lane, S.; Vargas, M.; Goldberg, B.; Bacchi, C. Trypanocidal activity of dicationic compounds related to pentamidine. Eur. J. Med. Chem. 2001, 36, 31-538.
108. Donkor, I. O.; Huang, T. L.; Tao, B.; Rattendi, D.; Lane, S.; Vargas, M.; Goldberg, B.; Bacchi, C. Trypanocidal activity of conformationally restricted pentamidine congeners. J. Med. Chem. 2003, 46, 1041-1048.
109. Borges, M. N.; Messeder, J. C.; Figueroa-Villar, J. D. Synthesis, anti-Trypanosoma cruzi activity and micelle interaction studies of bisguanylhydrazones analogous to pentamidine. Eur. J. Med. Chem. 2004, 39, 925-929.
110. Dardonville, C.; Brun, R. Bisguanidine, bis(2-aminoimidazoline), and polyamine derivatives as potent and selective chemotherapeutic agents against Trypanosoma brucei rhodesiense. Synthesis and in vitro evaluation. J. Med. Chem. 2004, 47, 2296-2307.
111. Huang, T. L.; Vanden Eynde, J. J.; Mayence, A.; Donkor, I. O.; Khan, S. I.; Tekwani, B. L. Anti-plasmodial and anti-leishmanial activity of conformationally restricted pentamidine congeners. J. Pharm. Pharmacol. 2006, 58, 1033-1042.
112. Bakunova, S. M.; Bakunov, S. A.; Wenzler, T.; Barszcz, T.; Werbovetz, K. A.; Brun, R.; Hall, J. E.; Tidwell, R. R. Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations. J. Med. Chem. 2007, 50, 5807-5823.
113. Kaminsky, R.; Schmid, C.; Brun, R. An "in vitro selectivity index" for evaluation of cytotoxicity of antitrypanosomal compounds. In Vitro Toxicol. 1996, 9, 315-324.
114. Patrick, D. A.; Bakunov, S. A.; Bakunova, S. M.; Kumar, E. V.; Lombardy, R. J.; Jones, S. K.; Bridges, A. S.; Zhirnov, O.; Hall, J. E.; Wenzler, T.; Brun, R.; Tidwell, R. R. Synthesis and in vitro antiprotozoal activities of dicationic 3,5-diphenylisoxazoles. J. Med. Chem. 2007, 50, 2468-2485.
115. Stephens, C. E.; Brun, R.; Salem, M. M.; Werbovetz, K. A.; Tanious, F.; Wilson, W. D.; Boykin, D. W. The activity of diguanidino and "reversed" diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donoVani. . Bioorg. Med. Chem. Lett. 2003, 13, 2065-2069.
116. Cory, M.; Tidwell, R. R.; Fairley, T. A. Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine). J. Med. Chem. 1992, 35, 431-438.
117. Bailly, C.; Perrine, D.; Lancelot, J. C.; Saturnino, C.; Robba, M.; Waring, M. J. Sequence-selective binding to DNA of bis(amidinophenoxy) alkanes related to propamidine and pentamidine. Biochem. J. 1997, 323 (Pt 1), 23-31.
118. Ismail, M. A.; Brun, R.; Easterbrook, J. D.; Tanious, F. A.; Wilson, W. D.; Boykin, D. W. Synthesis and antiprotozoal activity of azaanalogues of furamidine. J. Med. Chem. 2003, 46, 4761-4769.
119. Ismail, M.; Brun, R.; Wenzler, T.; Tanious, F.; Wilson, W.; Boykin, D. Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg. Med. Chem. 2004, 12, 5405-5413.
120. Arafa, R. K.; Brun, R.; Wenzler, T.; Tanious, F. A.; Wilson, W. D.; Stephens, C. E.; Boykin, D. W. Synthesis, DNA affinity, and antiprotozoal activity of fused ring dicationic compounds and their prodrugs. J. Med. Chem. 2005, 48, 5480-5488.
121. Ismail, M. A.; Arafa, R. K.; Brun, R.; Wenzler, T.; Miao, Y.; Wilson, W. D.; Generaux, C.; Bridges, A.; Hall, J. E.; Boykin, D. W. Synthesis, DNA affinity, and antiprotozoal activity of linear dications: terphenyl diamidines and analogues. J. Med. Chem. 2006, 49, 5324-5332.
122. Clement, B.; Immel, M.; Terlinden, R.; Wingen, F. J. Reduction of amidoxime derivatives to pentamidine in vivo. Arch. Pharm. (Weinheim) 1992, 325, 61-62.
123. Kamm, W.; Hauptmann, J.; Behrens, I.; Sturzebecher, J.; Dullweber, F.; Gohlke, H.; Stubbs, M.; Klebe, G.; Kissel, T. Transport of peptidomimetic thrombin inhibitors with a 3-amidino-phenylalanine structure: permeability and efflux mechanism in monolayers of a human intestinal cell line (Caco-2). Pharm. Res. 2001, 18, 1110-1118.
124. Clement, B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as prodrugs of amidines. Drug Metab. ReV. 2002, 34, 565-579.
125. Ansede, J. H.; Anbazhagan, M.; Brun, R.; Easterbrook, J. D.; Hall, J. E.; Boykin, D. W. O-Alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J. Med. Chem. 2004, 47, 4335-4338.
126. de Koning, H. P. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol. Pharmacol. 2001, 59, 586-592.
127. Zhang, X.; Berger, B. J.; Ulrich, P. Synthesis and trypanocidal activity of the bis-carba analogue of pentamidine. Bioorg. Med. Chem. Lett. 1996, 6, 1035-1036.
128. O'Brien, J.; Wilson, I.; Orton, T.; Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 2000, 267, 5421- 5426.
129. Baltz, T.; Baltz, D.; Giroud, C.; Crockett, J. Cultivation in a semidefined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. eVansi, T. rhodesiense, and T. gambiense. EMBO J. 1985, 4, 1273-1277.
130. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 1979, 16, 710-718.
131. Vennerstrom, J. L.; Arbe-Barnes, S.; Brun, R.; Charman, S. A.; Chiu, F. C. K.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Santo Tomas, J.; Scheurer, C.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Wittlin, S.; Charman, W. N. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004, 430, 900-904.
132. Werbovetz, K. A.; Sackett, D. L.; Delfin, D.; Bhattacharya, G.; Salem, M.; Obrzut, T.; Rattendi, D.; Bacchi, C. Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites. Mol. Pharmacol. 2003, 64, 1325-1333.
133. Werbovetz, K. A.; Brendle, J. J.; Sackett, D. L. Purification, characterization, and drug susceptibility of tubulin from Leishmania. Mol. Biochem. Parasitol. 1999, 98, 53-65.
134. Thuita, J. K.; Karanja, S. M.; Wenzler, T.; Mdachi, R. E.; Ngotho, J. M.; Kagira, J. M.; Tidwell, R.; Brun, R. Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis. Acta Trop. 2008, 108, 6-10.